Prestige Consumer Healthcare (PBH) Competitors

Interparfums (NASDAQ:IPAR) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap personal products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Is IPAR or PBH more profitable?

Prestige Consumer Healthcare has a net margin of 19.02% compared to Interparfums' net margin of 11.03%. Interparfums' return on equity of 16.45% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Interparfums	11.03%	16.45%	11.14%
Prestige Consumer Healthcare	19.02%	12.69%	6.79%

Which has more risk and volatility, IPAR or PBH?

Interparfums has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Does the media favor IPAR or PBH?

In the previous week, Prestige Consumer Healthcare had 18 more articles in the media than Interparfums. MarketBeat recorded 21 mentions for Prestige Consumer Healthcare and 3 mentions for Interparfums. Interparfums' average media sentiment score of 1.52 beat Prestige Consumer Healthcare's score of 0.56 indicating that Interparfums is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Interparfums	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prestige Consumer Healthcare	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of IPAR or PBH?

55.6% of Interparfums shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 43.7% of Interparfums shares are held by insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts rate IPAR or PBH?

Interparfums currently has a consensus target price of $162.00, suggesting a potential upside of 59.75%. Prestige Consumer Healthcare has a consensus target price of $93.33, suggesting a potential upside of 47.89%. Given Interparfums' stronger consensus rating and higher probable upside, research analysts clearly believe Interparfums is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Which has preferable earnings & valuation, IPAR or PBH?

Prestige Consumer Healthcare has lower revenue, but higher earnings than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.45B	2.24	$164.36M	$4.99	20.32
Prestige Consumer Healthcare	$1.14B	2.73	$214.60M	$4.26	14.81

Summary

Interparfums beats Prestige Consumer Healthcare on 11 of the 16 factors compared between the two stocks.